A Phase 2 interventional study of SD-101 dermal cream (6%) in Epidermolysis Bullosa, sponsored by Scioderm, Inc.. Terminated at 7 sites in United States. Open to participants aged 6 Months and older. Per ClinicalTrials.gov, last updated 2019-11-04.
Sponsored by Scioderm, Inc. (part of BioMarin Pharmaceutical) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 42 studies in Epidermolysis Bullosa with a site in United States — 10 open to participants now, 13 under way, 3 of them phase 3. Epidermolysis Bullosa · United States.
Among the 42 studies in Epidermolysis Bullosa with a site in United States, this one is the 7th largest by enrollment of the 37 interventional ones that give a count, is one of 2 that started in 2014, is one of 11 in phase 2, and was the 9th registered.
86 studies on the registry are indexed under Epidermolysis Bullosa; 17 are open to participants now.
Browse Epidermolysis Bullosa studies →10 of the 42 studies in Epidermolysis Bullosa with a site in United States are open now. Recruiting first, the newest first:
Johns Hopkins University · Sites in United States
Ages 5–21
Paradigm Therapeutics · Sites in United States
Ages 28 days–12 yrs
Xinnate AB · Sites in United States, France, Greece and 4 more countries
Ages 4+
BioMendics, LLC · Sites in United States
Ages 2+
M. Peter Marinkovich · Sites in United States
Ages 6+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 11 Epidermolysis Bullosa studies recruiting now, 9 (82%) set no upper age limit and 2 (18%) stop at 75 or younger; 10 take children under 18; 1 takes healthy volunteers.
This study: 6 Months and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
42 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 17 · Phase 3 8
First in 2007; this study’s year is marked. 2 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 42 is above the median of 14 across 67 interventional studies indexed under Epidermolysis Bullosa.
Median enrollment 16 across the 37 interventional studies, 60 across the 5 observational. Of the 26 that completed or were terminated, 16 (62%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 42 have an industry lead sponsor. The 10 most frequent:
This study is registered under Scioderm, Inc., one of the names counted as BioMarin Pharmaceutical. Under that name alone:
Scioderm, Inc. is the lead sponsor of 4 studies on the registry; none are open to participants now.
BioMarin Pharmaceutical has 5 studies filed under Epidermolysis Bullosa — fewer than ten, so there is no comparison to draw.
6 of the studies in Epidermolysis Bullosa with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07482787Phase 3Paradigm TherapeuticsEfficacy and Safety Study to Evaluate SD-101 in Epidermolysis Bullosa | 2027-05-17 |
| NCT07027345BioMendics, LLCA Phase II, Placebo Controlled, Clinical Trial of Topical TolaSure Targeting Aggregated Mutant Keratin in Epidermolysis Bullosa Simplex | 2027-01 |
| NCT06834035M. Peter MarinkovichTargeting Collagen VII Antibodies With IV IgG in Dystrophic Epidermolysis Bullosa | 2027-03 |
| NCT07050810Northwestern UniversityThera-Clean® Microbubbles System in Patients With Skin Diseases | 2027-06 |
| NCT06594393Xinnate ABA Phase 2 Study of TCP-25 Gel in Patients With Epidermolysis Bullosa, STEP-study | 2027-06-30 |
Add all 6 to your calendar (.ics) → With an account.
Among the 42 studies in Epidermolysis Bullosa with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study was to assess the continued safety of topical use of SD-101 cream (6%) in participants with Epidermolysis Bullosa (EB).
Funding Source: FDA Office of Orphan Products Development
This was an open-label extension study to assess the continued safety of topically applied SD-101 dermal cream (6%) in participants with Simplex, Recessive Dystrophic, and Junctional non-Herlitz EB.
SD-101 dermal cream (6%) was applied topically, once a day to the entire body for the duration of the study. Participants who successfully completed the entire SD-003 study (NCT02014376) had the option to roll over into the SD-004 study (NCT02090283). The baseline visit occurred at the final visit date for the SD-003 study. The body surface area (BSA) coverage of blisters and lesions assessment made at the final SD-003 study visit were used as the baseline information at the baseline visit for the SD-004 study. Participants returned to the study site for the following 13 visits (36 months) to have BSA assessed. BSA was assessed at all subsequent scheduled study center visits. Scheduled study center visits occurred every 6 months after Month 36 (Month 42, 48, and so on). After completion of Month 36, the next participant visit (Month 39) was a phone call from the site to the participant. Telephone visits occurred every 6 months thereafter (Month 45, 51, and so on) and included assessment of adverse events and concomitant medications only. For female participants of childbearing potential, a urine pregnancy test was performed at Month 6 and every 6 months up to and including the final study visit.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All participants applied SD-101 dermal cream topically, once a day, to the entire body for the duration of the study.
Drug: SD-101 dermal cream (6%)
SD-101 is a white, crystalline powder that is formulated within an odorless, soft, white cream base. SD-101-6.0 cream contains allantoin, a diureide glyoxylic acid, at a concentration of 6% and other excipients.
Also known as: SD-101, SD-101-6.0, Zorblisa
Number Of Participants With Treatment-Emergent Adverse Events (TEAEs)
Treatment-emergent adverse events were defined as adverse events that started or worsened on or after baseline visit, which occurred at the final visit date for the SD-003 study. A summary of serious and all other non-serious adverse events, regardless of causality, is located in the Reported Adverse Events module.
Time frame: From baseline to 30 days after last application of study drug (up to a maximum of 54 months)
Change From Baseline In Body Surface Area Index (BSAI) Of Lesional Skin At Month 24
Lesional skin was defined as areas that contained any of the following: blisters, erosions, ulcerations, scabbing, bullae, or eschars, as well as areas that were weeping, sloughing, oozing, crusted, or denuded. The percentage, ranging from 0% to 100%, of affected body surface area (BSA) was recorded for each defined body region (that is, head/neck, upper limbs, trunk \[includes groin\], and lower limbs), multiplied by the weighting factor, and then summed for all body regions to calculate the BSAI. The BSA for lesional skin was to be assessed by the same study physician on each visit for a particular participant. The mean change from baseline (final visit from the SD-003 study) in BSAI was assessed every 3 months. Only participants with data available for analysis at the specified time point are presented.
Time frame: Baseline, Month 24
42 participants with epidermolysis bullosa (EB) were enrolled in this open-label, multi-center extension study. All enrolled participants had previously completed Study SD-003 (NCT02014376).
| Milestone | Placebo to SD-101-6.0 | SD-101-3.0 to SD-101-6.0 | SD-101-6.0 to SD-101-6.0 |
|---|---|---|---|
| Started | 17 | 15 | 10 |
| Received at least 1 dose of study drug | 17 | 15 | 10 |
| Completed | 0 | 0 | 0 |
| Not completed | 17 | 15 | 10 |
| Withdrew: Withdrawal by subject | 6 | 6 | 6 |
| Withdrew: Sponsor terminated study | 6 | 6 | 1 |
| Withdrew: Lost to follow-up | 2 | 2 | 3 |
| Withdrew: Adverse event | 1 | 1 | 0 |
| Withdrew: Protocol violation | 2 | 0 | 0 |
Treatment-emergent adverse events were defined as adverse events that started or worsened on or after baseline visit, which occurred at the final visit date for the SD-003 study. A summary of serious and all other non-serious adverse events, regardless of causality, is located in the Reported Adverse Events module.
| Participants | Placebo to SD-101-6.0 | SD-101-3.0 to SD-101-6.0 | SD-101-6.0 to SD-101-6.0 |
|---|---|---|---|
| Any TEAE | 13 | 14 | 5 |
| Any TEAE Related to Study Drug | 1 | 1 | 0 |
| Any Fatal TEAE | 0 | 0 | 0 |
| Serious TEAE | 4 | 2 | 0 |
| Any TEAE Leading to Discontinuation | 1 | 1 | 0 |
Lesional skin was defined as areas that contained any of the following: blisters, erosions, ulcerations, scabbing, bullae, or eschars, as well as areas that were weeping, sloughing, oozing, crusted, or denuded. The percentage, ranging from 0% to 100%, of affected body surface area (BSA) was recorded for each defined body region (that is, head/neck, upper limbs, trunk \[includes groin\], and lower limbs), multiplied by the weighting factor, and then summed for all body regions to calculate the BSAI. The BSA for lesional skin was to be assessed by the same study physician on each visit for a particular participant. The mean change from baseline (final visit from the SD-003 study) in BSAI was assessed every 3 months. Only participants with data available for analysis at the specified time point are presented.
| percentage of BSAI | Placebo to SD-101-6.0 | SD-101-3.0 to SD-101-6.0 | SD-101-6.0 to SD-101-6.0 |
|---|---|---|---|
| Change From Baseline In Body Surface Area Index (BSAI) Of Lesional Skin At Month 24 | 1.99 ± 6.728 | -3.73 ± 6.152 | -9.50 ± 21.248 |
Collected over From baseline (Day 0) to 30 days after last application of study drug (up to a maximum of 54 months).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo to SD-101-6.0 | 0/17 (0%) | 4/17 (23.5%) | 13/17 (76.5%) |
| SD-101-3.0 to SD-101-6.0 | 0/15 (0%) | 2/15 (13.3%) | 13/15 (86.7%) |
| SD-101-6.0 to SD-101-6.0 | 0/10 (0%) | 0/10 (0%) | 5/10 (50%) |
| Event | Placebo to SD-101-6.0 | SD-101-3.0 to SD-101-6.0 | SD-101-6.0 to SD-101-6.0 |
|---|---|---|---|
| Benign breast neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/17 | 1/15 | 0/10 |
| Major depressionPsychiatric disorders | 0/17 | 1/15 | 0/10 |
| Suicide attemptPsychiatric disorders | 0/17 | 1/15 | 0/10 |
| Respiratory arrestRespiratory, thoracic and mediastinal disorders | 0/17 | 1/15 | 0/10 |
| AnaemiaBlood and lymphatic system disorders | 1/17 | 0/15 | 0/10 |
| LymphadenopathyBlood and lymphatic system disorders | 1/17 | 0/15 | 0/10 |
| BradycardiaCardiac disorders | 1/17 | 0/15 | 0/10 |
| CyanosisCardiac disorders | 1/17 | 0/15 | 0/10 |
| Abdominal painGastrointestinal disorders | 1/17 | 0/15 | 0/10 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 1/17 | 0/15 | 0/10 |
| Event | Placebo to SD-101-6.0 | SD-101-3.0 to SD-101-6.0 | SD-101-6.0 to SD-101-6.0 |
|---|---|---|---|
| PyrexiaGeneral disorders | 1/17 | 4/15 | 0/10 |
| Skin infectionInfections and infestations | 4/17 | 2/15 | 0/10 |
| PruritusSkin and subcutaneous tissue disorders | 2/17 | 3/15 | 0/10 |
| AnaemiaBlood and lymphatic system disorders | 3/17 | 0/15 | 0/10 |
| ConjunctivitisEye disorders | 0/17 | 2/15 | 0/10 |
| PainGeneral disorders | 0/17 | 2/15 | 0/10 |
| Ear infectionInfections and infestations | 2/17 | 2/15 | 0/10 |
| InfluenzaInfections and infestations | 1/17 | 2/15 | 0/10 |
| Nasal congestionRespiratory, thoracic and mediastinal disorders | 0/17 | 2/15 | 1/10 |
| Upper respiratory tract infectionInfections and infestations | 2/17 | 0/15 | 1/10 |
Safety: All participants who successfully rolled over into the SD-004 study from the SD-003 study and applied/were administered at least 1 dose of study drug.
| Age, Continuous(years) | Placebo to SD-101-6.0 | SD-101-3.0 to SD-101-6.0 | SD-101-6.0 to SD-101-6.0 | Total |
|---|---|---|---|---|
| Mean | 11.29 ± 10.385 | 15.70 ± 15.928 | 8.10 ± 4.795 | 12.11 ± 11.945 |
| Sex: Female, Male(Participants) | Placebo to SD-101-6.0 | SD-101-3.0 to SD-101-6.0 | SD-101-6.0 to SD-101-6.0 | Total |
|---|---|---|---|---|
| Female | 5 | 8 | 5 | 18 |
| Male | 12 | 7 | 5 | 24 |
| Ethnicity (NIH/OMB)(Participants) | Placebo to SD-101-6.0 | SD-101-3.0 to SD-101-6.0 | SD-101-6.0 to SD-101-6.0 | Total |
|---|---|---|---|---|
| Hispanic or Latino | 5 | 6 | 3 | 14 |
| Not Hispanic or Latino | 12 | 9 | 7 | 28 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Placebo to SD-101-6.0 | SD-101-3.0 to SD-101-6.0 | SD-101-6.0 to SD-101-6.0 | Total |
|---|---|---|---|---|
| Race — White/Caucasian | 16 | 15 | 7 | 38 |
| Race — Black or African-American | 1 | 0 | 2 | 3 |
| Race — Asian | 0 | 0 | 1 | 1 |
| EB Subtype(Participants) | Placebo to SD-101-6.0 | SD-101-3.0 to SD-101-6.0 | SD-101-6.0 to SD-101-6.0 | Total |
|---|---|---|---|---|
| Simplex | 4 | 4 | 3 | 11 |
| Recessive Dystrophic | 10 | 8 | 6 | 24 |
| Junctional non-Herlitz | 3 | 3 | 1 | 7 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Mar 2014 to primary completion in Sep 2018, 53 months.
Results were first posted in Nov 2019, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nelitolimod